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The World Health Organization (WHO) estimates that more than one billion people suffer from neglected tropical diseases.
Leishmaniasis is a widespread disease, affecting 12 million people around the world with about 1–2 million estimated
new cases occurring every year. Although pentavalent antimonial drugs are the most frequently prescribed treatments
for leishmaniasis, they produce severe side effects, including cardiotoxicity and hepatotoxicity. Other compounds, such
as amphotericin B, pentamidine and miltefosine, are second choice drugs, but they also produce side effects that can
endanger the patient’s life. Nowadays, there are two approaches to develop new therapies: one is the search for new drugs
and the other is the optimization of actual drug formulation. Traditional drug discovery takes 10 to 12 years in general
and involves high costs; around one billion dollars on average to develop a drug. A possibility to improve leishmaniasis
treatment would be the application of nanotechnology-drug delivery systems which can enhance the therapeutic potency
of existing drugs by optimizing their adsorption, distribution, metabolism and excretion (ADME) and reducing toxicity. In this
review we will discuss examples how nanotechnology-drug delivery systems have been used to improve the therapeutic
aspects of existing antileishmanial drugs.
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INTRODUCTION
Leishmaniasis is endemic in 98 countries, with 350 million
people at risk, in Asia, Africa, Southern Europe and South
and Central America. It is a complex of parasitic diseases
with two major manifestations, visceral leishmaniasis (VL)
and cutaneous leishmaniasis (CL).1 The estimated inci-
dence for VL and CL is 0.3 million and 1 million cases,
respectively.2 Moreover, VL has emerged as an important
opportunistic infection associated with HIV. In southern
Europe, up to 70% of cases of visceral leishmaniasis in
adults are associated with HIV infection.3
The etiologic agents are several different species,
all belonging to the genus Leishmania which maintain
their life cycle through transmission between an insect,
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a sandfly, and a mammalian host.45 Leishmania organisms
are dimorphic protists alternating between the promastig-
otes (in the insect vector) and the amastigotes (in verte-
brate hosts)6 (Fig. 1).
Pentavalent antimonials, the standard drugs for 70 years,
remain being used as first-line drugs in several parts
of the world as sodium stibogluconate (Pentostam® or
meglumine antimoniate (Glucantime®).89 Amphotericin B
(AmB) deoxycholate has been used since the early 1960s
as second-line treatment for leishmaniasis in the New
World, where resistance to pentavalent antimonials has
emerged.11 Alternatively, pentamidine isethionate, miltefo-
sine and paromomycin are available, but their use is lim-
ited due to toxicity or high cost of treatment (Fig. 2).12
Furthermore coinfection HIV-VL cases are less responsive
to each of these antileishmanial therapies presenting high
relapse rates or deaths due to concurrent illness compli-
cations and drug toxicity.3 Moreover, strains of the most
J. Biomed. Nanotechnol. 13, 117–133, 2017 119
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Figure 1. Life cycle of Leishmania. Modified from [7], K. J. Esch and C. A. Petersen, Transmission and epidemiology of zoonotic
protozoal diseases of companion animals. Clinical Microbiology Reviews 26, 58 (2013). © 2013.
Figure 2. Chemicals structures of miltefosine, pentamidine, paromomycin, meglumine antimoniate, sitamaquine, sodium sti-
bogluconate and amphotericin B.
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Table I. Current antileishmanial drugs, associated limitations and (possible) mechanism(s) of action.
Drug Administration Associated problems Mechanisms of action Refs.
Sodium
stibogluconate
(Pentostam®) and
Meglumine
antimoniate
(Glucantime®)
Parenteral Hepatotoxic, nephrotoxic and potentially
fatal cardiotoxic effects. Resistance in
Bihar, India
Inhibition of glycolysis and fatty acid
-oxidation
[1, 8, 35]
Amphotericin B
(Fungizone®)
Slow intravenous Nephrotoxicity, hypokalemia, rigors and
chills during infusion. Resistance not
documented
Presents high affinity for ergosterol, the
predominant sterol of the Leishmania
cell membrane
[36, 37]
Pentamidine Intramuscular Pain, nausea, vomiting, dizziness,
myalgia, hypertension, headache,
hypoglycemia, and transient
hyperglycemia
Interferes with DNA synthesis and
modifies the morphology of the
kinetoplast
[38]
Miltefosine Oral Contra-indicated in pregnancy.
Gastrointestinal effects,
nephrotoxicity, hepatotoxicity and
possible teratogenicity. Resistance
(due to inactivation of a P -type
ATPase)
Associated with phospholipid
biosynthesis and alkyl-lipid
metabolism in Leishmania
[8, 39, 8]
Paromomycin Topical for CL and
parenteral for VL
Erythema, pain, oedema, and
ototoxicity (damage to internal ear)
Inhibits translocation and recycling of
ribosomal subunits and hence protein
synthesis
[36, 38, 40]
Sitamaquine Oral Vomiting, abdominal pains, headache,
methemoglobinemia (for individuals
with glucose-6-phosphate
dehydrogenase deficiency) and renal
adverse effects
Unknown [36, 41]
human-infective Leishmania species are reported to be
resistant to standard chemotherapeutics13 (Table I). Hence,
development of new drugs for the treatment of leishmani-
asis is urgent.
Nowadays, there are two approaches to develop new
therapies: one is the search for new drugs and the other
is the optimization of actual drug formulation.14–22 Tradi-
tional drug discovery takes 10 to 12 years in general and
involves high costs; around one billion dollars on average
to develop a drug.23 A possibility to improve leishma-
niasis treatment would be the application of drug deliv-
ery systems which can enhance the therapeutic potency of
existing drugs by optimizing their adsorption, distribution,
metabolism and excretion (ADME) and reducing toxicity.
However, Leishmania poses an additional challenge to
drug delivery as the drug has to achieve therapeutic lev-
els at multiple sites (liver, bone marrow, spleen, cutaneous
lesions) and reach the parasites inside the phagolysosome
of macrophages. Thus, the development of systems that
are capable of delivering drugs and target parasites within
the host cells is crucial. Novel advances in nanotechnol-
ogy have proven beneficial in therapeutic fields such as
drug-delivery and gene/protein delivery and its applica-
tion in developing drug carriers has been useful for a
range of different diseases caused by parasitic or bacte-
rial pathogens such as leishmaniasis, malaria, Chagas dis-
ease and tuberculosis.24–31 In this context, researchers have
demonstrated the benefits of the use of nanotechnology to
improve the efficacy as well as to reduce the side-effects
and toxicity of the drugs used for treatment of these infec-
tious diseases.
Nanotechnology involves the engineering of macro-
molecular devices in the nanometer range and has already
been widely applied in medicine.3233 There are some
nanotherapeutics that have been approved by the FDA
(Food and Drug Administration) and are currently avail-
able for clinical use for different diseases such as fun-
gal infections and leishmaniasis (Abelcet®, AmBisome®
and Amphotec®, hepatitis (Pegasys® and PegIntron™),
HIV-associated sarcoma (DaunoXome® and many other
conditions.34 In this review we will discuss examples how
lipid-based colloid delivery systems have been used to
improve the therapeutic aspects of existing antileishmanial
drugs.
CURRENT STRATEGIES ON LEISHMANIASIS
TREATMENT
The current treatment for leishmaniasis is based on
chemotherapy and poses limitations such as toxicity, dif-
ficult route of administration and lack of efficacy on
parasitic infections in some endemic areas. Despite con-
siderable efforts to find new drugs against Leishmania
spp., the treatment of leishmaniasis is still based on the
use of the pentavalent antimonials sodium stibogluconate
and meglumine antimoniate, developed during the 1920s.
J. Biomed. Nanotechnol. 13, 117–133, 2017 121
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These drugs are known to have severe side effects, includ-
ing nausea, abdominal colic, diarrhea, skin rashes, hepa-
totoxicity, cardiotoxicity, nephrotoxicity and pancreatitis.
Electrocardiogram evaluation (cardiotoxicity) as well as
determination of serum levels of creatinine/urea (nephro-
toxicity) aminotransferases/alkaline phosphatase (hepato-
toxicity) and amylase (pancreatitis) all provide indications
for the high incidence of adverse events, especially of pan-
creatitis, which in HIV and VL coinfection have often been
associated with an increasing number of deaths.42 Another
problem associated to HIV-VL coinfection is the rise in the
number of relapse cases after the use of antimonials.4344
Furthermore, resistance to antimonials has been a growing
problem for approximately four decades.4546
Among the chemotherapeutic agents used as second-line
treatment for leishmaniasis, the polyene antibiotic AmB
and its liposomal formulation have been introduced for
use against VL.47 Although it is highly effective, even in
antimony-unresponsive patients, AmB has restrictions due
to its renal toxicity and requirement for inconveniently
slow intravenous administration.48 Liposomal AmB is pre-
ferred over conventional AmB because of its milder tox-
icity profile, but its use remains very limited as a result
of its high cost.49 Only in South America, pentamidine,
an aromatic diamine, has been used in the treatment of
CL,8 but severe adverse effects, including diabetes melli-
tus, hypoglycemia, shock, myocarditis and renal toxicity,
limit its use.50 Paromomycin is an aminoglycoside antibi-
otic with described leishmanicidal activity; however, this
drug has been documented to have variable efficacy in
different countries and is not commonly used or widely
available outside Africa and the Indian subcontinent.2551
Miltefosine, registered in 2002, is the first, and remains the
only, orally administered agent used for the treatment of all
types of leishmaniasis,384552 even though gastrointestinal
side-effects (anorexia, nausea, vomiting and diarrhea), hep-
atotoxicity and renal insufficiency have been reported.53
Despite efforts to fight this disease for the past 10 years,
and to allow the use of lipid formulations of AmB, mil-
tefosine and paromomycin for the treatment of leishmani-
asis, chemotherapy in many endemic countries, including
Brazil, is still based on pentavalent antimonials or conven-
tional AmB, notwithstanding their inherent toxicities and
complex route of administration.54
NOVEL NANOTECHNOLOGY-BASED
APPROACHES FOR ANTI-LEISHMANIAL
DRUG DELIVERY
General Information About Nanotechnologies for
Drug Delivery
Several authors reported the leishmanicidal activity of new
compounds, but some of them showed toxicity when tested
in vivo. Furthermore, the fact that the human pathogenic
forms of Leishmania, the amastigotes, reside within the
phagolysosome of macrophages can render it difficult for
the drugs to access the parasites. In this sense, nanotechno-
logical strategies have shown clear advantages both in effi-
cacy to target monocytes/macrophages intracellularly and
in overcoming toxicity problems (Table II).
In general, nanoformulations have been proposed pri-
marily as means to decrease the toxic effects of avail-
able drugs, to provide sustained drug release in addition to
improving their bioavailability, and to protect the incorpo-
rated drugs from being metabolized promptly, thus allow-
ing prolonged drug residence in the human body, and
therefore prolonging time between administrations.33
Nanomedicine is the field of science involved in the
design and development of nanotechnology-based ther-
apeutics and diagnostics with dimensions in the range
of 1 nm to 1000 nm.5556 The design of nanometer-
sized delivery systems for drugs represents one of the
most promising developments for antimicrobial thera-
pies because such systems may lead to treatments with
higher target delivery effect, resulting in higher therapeu-
tic efficacy and lower toxicity.57 Moreover, such systems
can improve bioavailability and protect the incorporated
drugs from being metabolized, causing prolonged drug
residence in the human body, and therefore allowing
to increase the time between administrations.33 Several
nanotechnological strategies, such as lipid-based colloid
systems,3758 nanostructured layered films,59 polymeric
nanoparticles6061 and silver nanoparticles62 have been
explored for precise drug delivery in leishmaniasis treat-
ment, increasing effectiveness and safety of drug therapy.
Many drugs are poorly soluble in aqueous phase which
compromise their distribution into and within the blood-
stream. Solubilization of hydrophobic drugs in colloidal
particles is a possible approach to overcome the prob-
lem of bringing a hydrophobic substance into the aqueous
blood compartment.
Nanoparticles (NPs) can be classified either by the
way in which they carry substances or by the char-
acteristics of the matrix. According to the classifica-
tion based on the type of material from which the
matrix is made one can distinguish organic nanoparti-
cles and inorganic nanoparticles.63 Nanotechnology-drug
delivery systems include organic NPs, liposomes, solid
lipid nanoparticles (SLNs), nanostructured lipid carri-
ers (NLCs), polymeric nanoparticles and microemulsions
(Fig. 3). The inorganic nanoparticles involve the use
of different inorganic oxides and have different sizes,
shapes, solubility, and long-term stability.64 They are usu-
ally synthesized by chemical reduction of the metallic
salt (gold/silver/silica/aluminum/titanium) with a reducing
agent.65
Liposomes
Liposomes are spherical vesicular structures that are com-
posed of phospholipid bilayers concentrically oriented
around an aqueous compartment that serve as carriers
122 J. Biomed. Nanotechnol. 13, 117–133, 2017
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Table II. Advantages and disadvantages of current nanomedicines.
Nanotechnology
based-system Advantages Disadvantages Reference
Liposomes Liposome increased drug stability via encapsulation;
Liposomes are non-toxic, flexible, biocompatible,
completely biodegradable; Liposomes increased
efficacy and therapeutic index of drug; Flexibility to
couple with site-specific ligands to achieve active
targeting; Use preferentially for parenteral or
cutaneous routes
Short half-life; Leakage and fusion of
encapsulated drugs; Production costs can
be high
[132]
Polymeric
nanoparticles
Avoid reticulo-endothelial system; High level of
biocompatibility to reduce cytotoxicity and
maximize tissue compatibility
[101]
Lipid nanocapsules Easy to scale-up; Encapsulating lipophilic and
hydrophilic drugs; Avoidance of organic solvents;
Use for cutaneous route
Toxicity related to surfactant [58]
Solid lipid
nanoparticles
Easy to scale-up and sterilize; Improve stability of
drugs; Encapsulating lipophilic and hydrophilic
drugs; Avoidance of organic solvents; Use for oral,
parenteral or cutaneous routes
Low drug loading and expulsion of matrix;
Short half-life; Toxicity related to surfactant
[58]
Nanostructured lipid
carriers
Improve stability of drugs; Improve loading of drugs
when compared with SLN; Long shelf-life; Easy to
scale-up and sterilize; Avoidance of organic
solvents; Use for oral, parenteral or cutaneous
routes
Toxicity related to surfactants [133]
Microemulsions Solubilize hydrophilic and lipophilic drugs; Easy
preparation; Long shelf-life; Thermodynamically
stables; Small size droplets (<0.22 m) and can
be sterilized by filtration; Use for oral, parenteral or
cutaneous routes
Large amount of surfactants; Toxicity related to
surfactant
of lipophilic or hydrophilic drugs.67 The main advantage
of liposomes is their ability to provide sustained drug
release, leaving the drug available in the blood circula-
tion for a long period of time, which increases the pro-
phylactic effect and reduces the drug dosage; additionally,
these structures are biocompatible with biological fluids,
decreasing the toxicity of drugs and limiting any local
inflammatory reactions.68–70 For antileishmanial therapy,
drug targeting can be achieved by liposomal encapsulated
drugs allowing them to reach the intracellular Leishmania
amastigotes; the drug containing liposomes naturally enter
in the macrophages by phagocytosis and hence deliver the
drugs passively to the phagolysosome where they then can
act directly on the parasites.71–73
Severe acute and chronic side effects have limited the
use of AmB deoxycholate as antileishmanial agent.74 Thus,
in an attempt to improve the pharmacokinetic properties
of the drug, the tolerability in the patient and to mini-
mize the side effects, three lipid-associated formulations
were developed and extensively used in clinical studies for
treatment of leishmaniasis.75–83
The commercial liposomal AmB, Ambisome, produced
by Gilead Sciences, is the only drug approved in 1997
by the FDA for VL treatment.84 Ambisome presented low
toxicity and high cure rate (above 90%) when compared to
AmB deoxycholate (Fungizone)8586 and is recommended
by the WHO as first-line therapy for treatment of VL
caused by L. donovani in India, Bangladesh, Bhutan and
Nepal or L. infantum in the Mediterranean Basin, Middle
East, Central Asia and South America.87 This liposomal
formulation is 350–750 times more active than meglumine
antimoniate and 2–5 times more active than free AmB.1186
Ambisome has been used to treat HIV-Leishmania coin-
fected patients;84 however, this treatment has not been
able to reduce relapse and mortality rates in cases of
such coinfected patients88 and unresponsiveness to Ambi-
some seemed to develop rapidly in co-infected patients.89
Although Ambisome is the most efficacious AmB liposo-
mal formulation, there are other formulations of this drug
currently available on the market: the colloidal formulation
Amphocyl in Europe (also called Amphotec in USA), the
injectable suspension Abelcet (USA), Fungisome (India),
and the emulsion Amphomul (India), but the administra-
tion and toxicity of the drug still pose problems in each of
these therapeutic alternatives.
The improvement of antimonial chemotherapy is urgent;
however, there are very few studies in experimental models
regarding the use of liposomes containing antimonials for
leishmaniasis treatment.7090–95 The meglumine antimoni-
ate liposomal formulation was 10-fold more effective than
the free drug against intracellular amastigotes of L. major
and five-fold more selective to the parasite with reduced
macrophage toxicity. It was observed that the uptake of
meglumine antimoniate containing liposomes was higher
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Figure 3. Conventional lipid-based colloidal carriers. Schematic differences between liposomes, lipid nanocapsules, polymeric
nanoparticles, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs) and microemulsions drug delivery systems.
Modified from [66], B. Fonseca-Santos, et al., Nanotechnology-based drug delivery systems for the treatment of alzheimer’s
disease. International Journal of Nanomedicine 10, 4981 (2015). © 2015.
than that observed for non-infected macrophages which
could have contributed to the improvement of the selectiv-
ity index.91
A macrophage possesses many receptors on its sur-
face involved in control of its cellular processes such as
activation, recognition, endocytosis and secretion. Incor-
poration of ligands into liposomes capable of interact-
ing with macrophage receptors has been used to enhance
the uptake of liposomal content by the macrophages.96
Mannose and 4-sulphated N -acetyl galactosamine bear-
ing liposomes showed increased antileishmanial activity
and enhanced intracellular localization of AmB compared
to unmodified liposomes.97 Other macrophage–specific
ligands such as tuftsin residues and phosphatidylserine
have also been incorporated into liposomes resulting
into improved macrophage targeting of antileishmanial
agents.919899
Polymeric Nanoparticles
Polymeric nanoparticles are composed of a polymeric
matrix, which can be made of synthetic or natural
polymers.100 They present a high level of biocom-
patibility to reduce cytotoxicity and maximize tissue
compatibility, by their formulation from either natural
or synthetic polymers.101 The synthetic polymers most
widely used are polyesters such as polylactide (PLA),
polylactide–polyglycolide copolymers (PLGA), polycapro-
lactones (PCL), and polyacrylates (PCA); examples of
natural polymers employed are albumin and chitosan.102
The most commonly used polymer is PLGA and several
PLGA-drug delivery systems have been approved by the
FDA.103 Polymeric nanoparticles are prepared by several
methods, such as solvent evaporation, spontaneous emul-
sification, solvent diffusion or polymerization.104
The first researchers who evaluated the poten-
tial of polymeric nanoparticles against leishmania-
sis were Gaspar and coworkers.105 They developed
primaquine-loaded poly-alkylcyanoacrylate nanoparticles
against L. donovani-infected macrophages. This formu-
lation was shown to be 21 times more effective than
the free drug in clearance of the parasite.105 AmB has
also been employed in the development of some poly-
meric nanoparticles. In some studies, PLGA nanoparti-
cles with AmB have been developed and were tested
against in vitro cultured promastigotes and intracellular
amastigotes of L. infantum. Moreover, their in vivo biolog-
ical activity was determined in a mouse model and com-
pared with that of the commercial solution AmBisome in
doses of 2.5 and 5.0 mg/Kg AmB equivalents by intra-
venous administration. PLGA nanoparticles appeared to
be equally effective as AmBisome against the different
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Leishmania life-cycle stages in the in vitro assays and
superior in in vivo efficacy.106 Another study developed
AmB nanoencapsulated in PLGA and dimercaptosuccinic
acid (DMSA) nanoparticles. Their efficacy was evaluated
in the treatment of experimental cutaneous leishmaniasis
in C57BL/6 mice. AmB-coated PLGA–DMSA nanoparti-
cles showed the same efficacy as free AmB to reduce paw
diameter; however, the treatment with these nanoparticles
also promoted a significantly greater reduction in parasite
number and cell viability compared with the free drug.107
Lipid Nanocapsules
Lipid nanocapsules (LNs) are biomimetic carriers that
mimic lipoprotein with size ranges from 20 to 100 nm.
These carriers are composed of a lipid core surrounded
by a membrane made from surfactant characterized by a
hybrid structure between polymer nanocapsules and lipo-
somes. Their preparation involves a method based on the
phase inversion principle of an oil/water (O/W) system
upon thermal manipulation. Unlike liposomes which are
manufactured through processes involving organic solvent
and are leaky and unstable in biological fluids, LNs are
prepared by solvent-free methods, and “soft-energy” tech-
nology and present great stability (with physical stabil-
ity up to 18 months). In addition, besides the advantage
of high drug bioavailability, it is important to empha-
size that LNs containing drugs are able to deliver their
content directly to the target site at a reducible dosage
(10,000 fold), thus leading significantly to the preven-
tion or at least reduction of any side effects to acceptable
levels.108109
The potential of targeting and drug delivery of LNs
to specialized phagocytes via phosphatidylserine (PS)-
specific ligand-anchored nanocapsules bearing doxorubicin
(DOX) has been evaluated. Kansal and coworkers showed
that LN containing doxorubicin (LN-DOX) had a 1.75-fold
higher uptake if PS is anchored onto its surface compared
with non-PS containing LN-DOX and that the former
favored delivery into the cell cytoplasm.24 PS containing
LN had a lower IC50 value against L. donovani, probably
as a consequence of better uptake of PS-containing LN
as both formulations had similar entrapment efficiencies
(80%). Therefore, PS can improve uptake by macrophages
by binding to ligands present on the surface of the cell or
the carrier system.24
Miltefosine is a membrane-active alkylphospholipid
administered orally for treatment of leishmaniasis.
Its mechanism of action may involve disturbance of cal-
cium homeostasis in Leishmania.110 Electron paramag-
netic resonance (EPR) spectroscopy studies showed that
this drug causes dramatic injuries in the membrane of
Leishmania promastigotes.111 In studies of drug deliv-
ery of miltefosine-loaded LNs, these formulations showed
high entrapment efficiency, good colloidal properties, sus-
tained release of the drug and physical stability. It is
possible to design unique nanodevices combining the
biological activity of a drug with the biopharmaceuti-
cal advantages of LNs, and allowing targeting via the
oral route. From a clinical point of view it is important
that available data suggest the feasibility of a single-dose
oral nanomedicine for enhanced therapy of schistosomi-
asis caused by Schistosoma mansoni and possibly other
diseases like leishmaniasis.112
Although there are few studies regarding the effective-
ness of this nanocarrier against Leishmania spp, its struc-
ture has shown advantages such as the ability to deliver
hydrophobic/hydrophilic drugs, the increased uptake of
drugs by the cell, the possibility for both parenteral and
oral delivery, and the feasibility to target drugs.90113
Solid Lipid Nanoparticles (SLNs) and
Nanostructured Lipid Carriers (NLCs)
Among the nanocarriers, solid lipid nanoparticles (SLNs)
and nanostructured lipid carriers (NLCs) are the most
promising.114 SLNs are prepared by using physiologically
tolerated solid lipid components and are applied for admin-
istration of lipophilic drug molecules. However, SLNs
have major drawbacks of low drug loading and possible
drug expulsion due to a propensity for lipid crystalliza-
tion or transformation during storage procedures (Table II).
To overcome these disadvantages, NLCs have been intro-
duced with a matrix made up of a mixture of solid and liq-
uid lipids. SLNs and NLCs have several advantages such
as low cost and safety compared to other colloidal carriers
including liposomes, microemulsions and nanocapsules.115
Although NLCs possess a higher capacity for drug incor-
poration than SLNs,58113116 this formulation has not yet
been evaluated as alternative administration for therapy of
leishmaniasis.
Paromomycin has been the most intensively studied
compound with regard to the potential topical treatment
for leishmaniasis.117 Conventional topical dosage forms
of paromomycin had already been tested previously, but
despite the promising results obtained, the efficacy was
limited due its physicochemical properties and different
constituents present in ointments formulations which con-
tribute to insufficient concentration of paromomycin at the
sites of infection after topical administration.118–125 For the
treatment of CL, drugs topically applied must be able to
cross the skin and reach the Leishmania amastigotes within
the phagolysosomes of infected macrophages localized in
the deep dermal layer of the skin.
The therapeutic potential of SLNs has been evaluated
in different studies such as cancer126 and parasitic diseases
such as malaria,127 human African trypanosomiasis128 and
CL.129 Particularly for CL, SLNs could improve the inter-
action of the drug with the stratum corneum and other lay-
ers of the skin and thus provide the possibility of topical
administration with controlled release, reduced drug toxi-
city and so to optimize its treatment.129130 Paramomycin-
containing SLN has been previously described130 and
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showed potent activity against L. major and L. trop-
ica intracellular amastigotes when compared to free
paromomycin; the cytotoxicity of paramomycin-SLN for-
mulation is size dependent.131 These results showed that
delivery of drugs to macrophages via nanoparticles is fea-
sible; however, additional studies are necessary in order
to investigate the in vivo antileishmanial potential of this
antibiotic formulation.
In a similar way, Gupta and coworkers developed AmB
containing SLN as well as AmB loaded in modified SLN
coated with the macrophage-specific ligand, O-palmitoyl
mannan.10 The antileishmanial activity of free and SLNs
entrapped AmB was tested in vitro against a L. donovani
infected macrophage-amastigote system (J774A.1 cells),
which showed higher efficacy of the AmB-modified SLNs
over AmB-SLNs and free drug. Both formulations were
also able to target infected macrophages in the liver and
spleen of mice which demonstrates the potential of these
formulations as therapeutic alternative to treat VL.10
Among all its sophisticated mechanisms of evasion
of the host immune system134–142 is Leishmania’s capa-
bility of preventing the generation of pro-inflammatory
cytokines143 and activating a Th2 type immune response.
Therefore, stimulation of Th1 and suppression of Th2
immune responses are considered a promising therapeu-
tic strategy for leishmaniasis.144 It is known that the
aminopolysaccharide chitosan stimulates macrophages to
produce several proinflammatory cytokines including IL1,
IL6, TNF- and nitric oxide (NO).144–146 Thus, AmB-SLN
bound to chitosan successfully exhibited low toxicity and
improved the therapeutic effect against L. donovani intra-
cellular amastigotes, probably because of an enhancement
of NO production during the TH1 cell response which
could explain its efficacy over amphotericin loaded SLN
and free AmB.129
Microemulsions
Microemulsions are translucent, stable, isotropic mixtures
of oil, water and surfactant, frequently in combination with
a cosurfactant, with a size of approximately 100 nm. Such
a mixture may form hydrophilic aggregates in oil (water-
in-oil system, W/O), hydrophobic aggregates in water
(oil-in water system, O/W), and also bi-continuous sys-
tems, such as a mixture of W/O and O/W, in which the
dispersed phase is in the nanometer size range. Microemul-
sions have generated considerable interest over the years
as potential drug delivery systems.147148 The existence of
microdomains of different polarity within the same single-
phase solution improves drug solubilization and protec-
tion against enzymatic hydrolysis, while a potential to
increase drug absorption is provided by the surfactant that
induces membrane fluidity and thus permeability. Despite
the huge therapeutic potential of microemulsions in leish-
maniasis treatment, there are few reports about it in the
literature, most of them merely describing the preparation
of AmB or the promising experimental drug buparvaquone
loaded microemulsions rather than their potential biologi-
cal application.149
Other Nanocarriers
Currently, new nanosystems are being developed. One
of the most popular technologies involves carbon nano-
structures such as nanotubes.63 Carbon nanotubes have
engrossed remarkable attention as the most promis-
ing nano-material in the 21st century for numerous
applications.152153
AmB has been attached to functionalized carbon
nanotubes. This new formulation of AmB (f-CNT–AmB)
exhibited significantly higher efficacy against in vitro intra-
cellular amastigotes of L. donovani than that of free AmB.
The in vivo toxicity assessment of the compounds in
BALB/c mice revealed no hepatic or renal toxicity. More-
over, f-CNT-AmB inhibited the amastigote replication in
hamsters by 90%, instead of treatment with free AmB that
caused 69% inhibition.154
Another study involved the test of a formulation of
betulin (BET) attached to functionalized carbon nano-
tubes (f-CNTs) against L. donovani. The fCNT-BET was
12-fold more effective against intracellular amastigotes
than BET alone with no significant cytotoxicity observed
on host cells.155
ABSORPTION AND DISTRIBUTION OF
NANOPARTICLES
The absorption and distribution profile of a nanoparticle is
greatly determined by physicochemical properties such as
size, charge, hydrophobicity, and targeting molecules, and
these properties are dependent on the type of the delivery
system156 (Fig. 4).
The size of the nanoparticle is important for its entry
into cells, its interactions with the immune system, and its
clearance.158 Cell uptake mechanisms are partially depen-
dent on size. Endocytosis is the process through which
nanoparticles or small molecules enter cells; the specific
type of endocytosis through which the nanoparticle enters
the cell determines the translocation of the entrapped
molecule inside the endosome.159 Hydrophobicity affects
cellular uptake, distribution, interaction with immune cells
and plasma proteins, and clearance from the body.158160
Charge is important for mucoadhesion or diffusion, cel-
lular uptake, and toxicity. Targeting affects biodistribution
and immune responses.158
These physicochemical characteristics of the nanopar-
ticle surface also play a decisive role in uptake. Passive
vectoring is related to the inherent capacity of phago-
cytic cells when they recognize substances foreign to
the organism.63 According to the physicochemical char-
acteristics of the nanocarrier and the nature of the target
cells, two main internalization pathways may occur: either
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Figure 4. Properties of nanoparticles such as size, surface, charge and hydrophobicity that each, by different mechanisms, may
affect the efficacy of drug delivery. Modified from Dobrovolskaia and McNeil, 2007 and [157], J. Lazarovits, et al., Nanoparticle-
blood interactions: The implications on solid tumour targeting. Chemical Communications 51, 2756 (2015). © 2015.
phagocytosis or other endocytic pathways (macropinocy-
tosis or endocytosis) (Fig. 5).102
Distribution and uptake can also be driven by active vec-
toring. This involves the addition of specific compounds
(ligands) to the nanoparticle surface. Such ligands favor
interactions with the cell membrane, thus enhancing the
recognition of nanoparticles by cells.161162
The ligand is chosen dependent on its stability and
selectivity with regard to the target cells. Other factors
such as availability and interactions with immunologic
cells or with membranes are also taken into account.63 It is
noteworthy that polymeric nanoparticles and liposomes,
whose structure and chemical composition strongly differ,
still show similar interactions with macrophages, based on
their surface electric charge. Liposomes displaying a nega-
tively charged surface, generally containing the negatively
charged phospholipids phosphatidylserine (PS) and phos-
phatidylglycerol (PG), exhibit a much higher binding to
and phagocytosis by macrophages as compared to neu-
tral vesicles.163164 Indeed, up-regulation of the level of
negatively charged PS in the outer leaflet of the Leish-
mania spp. amastigote plasma membrane was recently
demonstrated. This seems to be highly relevant for their
attachment to macrophages,165 as negatively charged phos-
pholipids expressed in the outer membrane leaflet of cells
are recognized by macrophages (via scavenger receptors)
as apoptotic cells.166
COST EFFECTIVENESS ANALYSIS OF
THERAPY-BASED NANOTECHNOLOGY
AND DRAWBACKS
Commercial feasibility is the most desired characteristic of
any novel delivery system and it is governed by the cost of
the material and the ease of manufacturing and scale up.
Although liposomal AmB is currently the most effec-
tive strategy, this drug is quite expensive resulting in
higher cost-effectiveness.168 The higher the dosage, the
more expensive the treatment. Indeed, the cost (estimates
presented in 2008 US dollars, US$) per patient treated with
Ambisome varied from $153.4 (10 mg/kg, single dose)
to $300 (20 mg/kg of L-AmB for 4 days). In order to
reduce the cost of treatment, clinical trials involving coad-
ministration of Ambisome with other antileishmanial drugs
were conducted. The estimated total cost of the treatment
for combination therapy per patient is $129 and $132 for
Ambisome along with miltefosine and Ambisome along
with paromomycin, respectively, compared with $153 for a
single dose of Ambisome (10 mg/kg).168169 The cost limi-
tations of Ambisome were counter balanced to some extent
by a donation program involving Gilead Sciences and
WHO in 2012 that involved the donation of 450,000 vials
of Ambisome with their distribution to all beneficiary
countries in 2013. However, the lyophilized Ambisome is
not stable at temperatures above 25 C (kept lyophilized)
or even at 2–8 C (when reconstituted in sterile water)
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Figure 5. Main internalisation pathways of mammalian cells.
(a) Phagocytosis is an actin-based mechanism occurring pri-
marily in macrophages, and fully associated with opsoniza-
tion. (b) The process by which clathrin-coated vesicles
are produced involves interactions of multifunctional adap-
tor proteins with the plasma membrane, with the forma-
tion of a clathrin lattice and a dependence on the GTPase
dynamin. (c) Caveolae are one source of clathrin-independent
or raft-dependent endocytosis. Caveolae-mediated endocyto-
sis occurs in typical flask-shaped invaginations of the mem-
brane coated with caveolin dimers, also with a dependence
on dynamin. (d) The formation of macropinosomes involves
actin-based deformation and remodeling of the cell mem-
brane and is regulated by mechanical stimuli to which cells
are exposed. Macropinocytosis is an actin-based pathway,
engulfing extracellular milieu with nanoparticles; it has a poor
selectivity. (e) Other endocytosis pathways can be involved
in the nanoparticle internalization, independent of clathrin,
caveolae and actin. Modified from [102, 167], H. Hillaireau
and P. Couvreur, Nanocarriers’ entry into the cell: Rele-
vance to drug delivery. Cellular and Molecular Life Sciences
66, 2873 (2009). © 2009 and K. Murugan, et al., Parameters and
characteristics governing cellular internalization and trans-
barrier trafficking of nanostructures. International Journal of
Nanomedicine 10, 2191 (2015). © 2015.
which limits its use in the field in most of the affected
countries.170171
The commercial scenario for SLN is promising. SLNs
are based on triglyceride lipids which are less expensive
than phospholipids and their manufacturing process and
scaling up are feasible.113 The scale up and manufacture
process are also possible when microemulsions are used
as template for SLN production.172
PERSPECTIVES AND CONCLUSION
Targeting of antileishmanial drugs to infected macrophages
via novel drug delivery systems presents a promising
approach to overcome the limitations associated with the
current treatment protocols. The unmodified and surface
engineered drug carriers resulted in the reduced toxicity
and increased effect of drug on the Leishmania parasites.
The development of drug delivery systems will allow to
overcome not only toxicity and drug effectiveness but also
contribute to lower costs which will not only benefit the
treatment of patients with leishmaniasis but also accelerate
the development of systems for other serious (sub)tropical
infectious diseases such as malaria, Chagas disease, tuber-
culosis, schistosomiasis among others.
Despite the promising results involving nanotechnology-
drug delivery systems in the treatment of leishmaniasis,
the results obtained so far are mainly based on preclinical
studies and, consequently, patients have not entirely yet
been benefited. The next step will thus be to conduct clin-
ical trials to confirm the results already obtained. Indeed,
despite the need to improve antimonial chemotherapy and
the extremely promising results obtained with liposomes in
experimental models of leishmaniasis, no pharmaceutical
composition associating lipid formulations with an antimo-
nial has reached commercialization so far. The meglumine
antimoniate, for instance, presents low drug encapsulation
efficiency in liposomes due to its hydrophilic property as
well as short-term stability, thus it is necessary to develop
other nanotechnology-based drug delivery systems to over-
come these problems.
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